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L

oss of 53BP1 rescues BRCA1 deficiency and is associated with BRCA1-deficient and triple-negative
breast cancers (TNBC) and with resistance to genotoxic drugs. The mechanisms responsible for decreased
53BP1 transcript and protein levels in tumors remain unknown. Here, we demonstrate that BRCA1 loss activates
cathepsin L (CTSL)–mediated degradation of 53BP1. Activation of this pathway rescued homologous recombination repair and allowed BRCA1-deficient cells to bypass
growth arrest. Importantly, depletion or inhibition of CTSL
with vitamin D or specific inhibitors stabilized 53BP1 and
increased genomic instability in response to radiation

and poly(adenosine diphosphate–ribose) polymerase inhibitors, compromising proliferation. Analysis of human
breast tumors identified nuclear CTSL as a positive biomarker for TNBC, which correlated inversely with 53BP1.
Importantly, nuclear levels of CTSL, vitamin D receptor,
and 53BP1 emerged as a novel triple biomarker signature
for stratification of patients with BRCA1-mutated tumors
and TNBC, with potential predictive value for drug response. We identify here a novel pathway with prospective relevance for diagnosis and customization of breast
cancer therapy.

Introduction

Correspondence to Susana Gonzalo: sgonzalo@slu.edu

of several genes (Scully and Livingston, 2000; Mullan et al.,
2006; Zhu et al., 2011). In addition, BRCA1 function is linked
to epigenetic mechanisms such as DNA methylation and miRNA
biogenesis (Shukla et al., 2010; Kawai and Amano, 2012; Tanic
et al., 2012).
Recruitment of BRCA1 to DNA DSBs facilitates repair
by homologous recombination (HR), and loss of BRCA1 results
in genomic instability characterized by unrepaired DNA breaks
and complex chromosomal rearrangements that compromise cell
viability (Scully et al., 1997a; Moynahan et al., 1999; Snouwaert
et al., 1999). As such, BRCA1 knockout mice and mice carrying
a BRCA1 deletion mutant (BRCA111/11) are embryonic lethal
(Xu et al., 2001; Evers and Jonkers, 2006). Although lethality

Abbreviations used in this paper: CTSL, cathepsin L; DSB, DNA double strand
break; HR, homologous recombination; Hscore, immunohistochemical score;
IR, ionizing radiation; IRIF, IR-induced foci; MEF, mouse embryonic fibroblast;
NHEJ, nonhomologous end joining; PARPi, poly(ADP-ribose) polymerase inhibitor; qRT-PCR, quantitative RT-PCR; TMA, tissue microarray; TNBC, triplenegative breast cancer; VDR, vitamin D receptor.
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BRCA1 is a well-established tumor suppressor, and women
carrying germline mutations in BRCA1 have a high risk of
developing breast and ovarian cancer (Neuhausen and Marshall,
1994; Wooster and Weber, 2003). Tumors that arise often lack
expression of estrogen and progesterone receptors and Her2,
being classified as triple-negative breast cancers (TNBC;
Turner and Reis-Filho, 2006). BRCA1 participates in DNA
double-strand break (DSB) repair, S and G2/M phase cellcycle checkpoints after damage, control of centrosome numbers,
maintenance of heterochromatin, and transcriptional regulation
I. Gonzalez-Suarez and A. Novell contributed equally to this paper.
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in BRCA111/11 mice can be rescued by abrogation of ATM,
Chk2, or p53, these mice ultimately develop tumors and premature aging (Cao et al., 2006). Recently, loss of the DNA
repair factor 53BP1 was shown to rescue embryonic lethality
in BRCA1-deficient mice while maintaining a low incidence
of tumorigenesis and normal aging (Cao et al., 2009). This is
in contrast to 53BP1 knockout mice, which are cancer prone
(Ward et al., 2003), suggesting that 53BP1 contributes to the
developmental defects of BRCA1-deficient mice and that 53BP1
loss has different consequences for cancer and aging in the context of BRCA1 proficiency or deficiency.
Loss of 53BP1 promotes viability of BRCA1-deficient
cells by rescuing HR function (Cao et al., 2009; Bouwman
et al., 2010; Bunting et al., 2010). Importantly, down-regulation
of 53BP1 was observed in human BRCA1-related breast cancer
and TNBC and was suggested to allow these tumors to overcome the genomic instability caused by HR defects (Bouwman
et al., 2010). 53BP1 facilitates DNA DSB repair by nonhomologous end joining (NHEJ; Schultz et al., 2000; FernandezCapetillo et al., 2002; Wang et al., 2002; Xie et al., 2007) and
also affects HR via inhibition of BRCA1-mediated DSB endresection (Bunting et al., 2010). The current model is that
BRCA1 deficiency hinders end-resection of DSBs by CtIP and
the Mre11–Rad50–Nbs1 complex, an essential event in HR.
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Accumulation of 53BP1 in this context promotes indiscriminate
NHEJ and chromosomal instability that ultimately causes proliferation arrest or cell death. Conversely, in cells double deficient
in BRCA1 and 53BP1, end-resection is allowed, rescuing HR
(Bunting et al., 2010). Consistent with this model, 53BP1 loss
reduces the sensitivity of BRCA1-deficient cells to genotoxic
agents such as cisplatin and mitomycin C (Bouwman et al.,
2010) and to poly(ADP-ribose) polymerase inhibitors (PARPi;
Farmer et al., 2005; Bunting et al., 2010), compounds at the
forefront for breast cancer therapy (Gartner et al., 2010). Thus,
BRCA1-deficient cells are thought to down-regulate 53BP1 as
a means to ensure proliferation/viability.
Up-regulation of 53BP1 levels represents a promising strategy for treatment of breast tumors with the poorest prognosis and
for improving their response to PARPi and other DNA-damaging
strategies. However, we lack knowledge about how 53BP1 mRNA
and protein levels are down-regulated in cancer cells. We previously
identified a pathway regulating 53BP1 protein levels (GonzalezSuarez et al., 2011; Redwood et al., 2011a,b). Up-regulation of the
cysteine protease cathepsin L (CTSL) leads to accumulation of the
protease in the nucleus, degradation of 53BP1 protein, and defects
in NHEJ. Importantly, inhibition of CTSL activity by treatment
with vitamin D or specific inhibitors stabilizes 53BP1 protein
levels and rescues NHEJ defects (Gonzalez-Suarez et al., 2011).
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Figure 1. Bypass of growth arrest after BRCA1 loss
is associated with CTSL up-regulation and 53BP1 degradation. (A) MCF7 cells were lentivirally transduced
with an shRNA for depletion of BRCA1 (shBRCA1)
or a control shRNA scrambled (sh scr) and BRCA1
levels were assessed by Western blot immediately
after selection. (B) Proliferation rate shows that BRCA1
depletion induces growth arrest. The mean ± SD of
three independent experiments is shown (SD too
small to show at some time points). (C) Western blots
show 53BP1 and CTSL levels in growth-arrested cells.
(D) Proliferation rate of BRCA1-deficient cells that overcome growth arrest. The mean ± SD of three independent experiments is shown (SD too small to show
at some time points). (E) Western blots show levels
of BRCA1, 53BP1, and CTSL in control and BOGA
cells (representative experiment of 25 biological repeats). (F) Relative expression of BRCA1, CTSL, and
53BP1 in control and BOGA cells as determined by
qRT-PCR. The mean ± SD of three independent experiments is shown. Asterisk shows p-value of statistical
significance (*, P ≤ 0.05). NS, not statistically significant differences. (G) Western blots show BRCA1
and 53BP1 levels upon reconstitution of BRCA1 by
transient transfection into BRCA1-deficient cell lines—
BOGA cells (left) and HCC1937 (right). An empty
vector (EV) was used as control. -Tubulin was the
loading control.
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Here, we demonstrate that BRCA1-deficient cells activate
CTSL-mediated degradation of 53BP1 as a means to overcome
genomic instability and growth arrest. In addition, depletion or
inhibition of CTSL in these cells increases genomic instability
in response to ionizing radiation (IR) or PARPi. Lastly, we identify high levels of nuclear CTSL and low levels of 53BP1 and
vitamin D receptor (VDR) as a novel signature in subsets of
breast cancer patients. We envision that the status of nuclear
CTSL, VDR, and 53BP1 could be used for customization of
breast cancer therapy.

Results
BRCA1-deficient cells activate CTSLmediated degradation of 53BP1
to bypass growth arrest

Previous studies demonstrated that loss of 53BP1 rescues the
BRCA1-deficient phenotype (Cao et al., 2009; Bouwman et al.,
2010; Bunting et al., 2010). We also showed that CTSL regulates
the stability of 53BP1 (Gonzalez-Suarez et al., 2011; Redwood
et al., 2011a,b). Here, we investigated whether breast tumor cells
are able to down-regulate 53BP1 upon loss of BRCA1 to restore
proliferation/viability and if CTSL is one of the factors responsible
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Figure 2. CTSL is responsible for the degradation of 53BP1 that allows bypass of growth
arrest in BOGA cells. (A) MCF7 cells were
transduced with sh53BP1, shBRCA1, or both.
After selection, BRCA1, 53BP1, and CTSL levels
were monitored by Western blot. (B) Graphs
compare proliferation rates between control
cells and 53BP1/BRCA1-depleted cells (left)
and between 53BP1/BRCA1-depleted cells
and BRCA1-depleted cells (right). Depletion
of 53BP1 prevents growth arrest upon BRCA1
loss (representative experiment of three biological repeats). (C) Control and BOGA cells were
transduced with shCTSL or control shRNA (sh
luc) and the levels of CTSL, BRCA1, and 53BP1
were monitored by Western blot. Vertical lines
show where gel pieces were juxtaposed. (D) Con
trol or BOGA cells were treated with vitamin D
(107 M) or vehicle (BGS) for 24 h and the
levels of 53BP1 and p107, a known target of
CTSL degradation, were monitored by Western blot. (E) Control or BOGA cells were incubated with the broad cathepsin inhibitor E-64
(10 µM) or with vehicle (H2O) for 24 h, and
the levels of 53BP1 and CTSL were monitored
by Western blot. Note how cathepsin inhibition stabilizes 53BP1. (F) MCF7 cells growing
asynchronously or growth arrested for 48 h
by serum deprivation were analyzed for cell
cycle profile (left) and for levels of CTSL, 53BP1,
and BRCA1 by Western blot (right). Representative experiment of three biological repeats.
Either Lamin A/C or -tubulin was used as
loading control.

for the depletion of 53BP1. The human breast cancer cell line
MCF7, which is BRCA1 and 53BP1 proficient, was depleted
of BRCA1 via lentiviral transduction with shRNAs (Fig. 1 A
and Fig. S1 A). As previously shown in human fibroblasts
(Tu et al., 2011), depletion of BRCA1 in MCF7 cells induces
growth arrest (Fig. 1 B). BRCA1-deficient cells did not show differences in the levels of 53BP1 or CTSL proteins immediately after
growth arrest (Fig. 1 C). Interestingly, after approximately two
weeks in culture, BRCA1-deficient cells resumed proliferation,
albeit at a slower rate than control cells (Fig. 1 D). Importantly,
BRCA1-deficient cells that overcome growth arrest (herein
referred to as BOGA cells, for clarity) exhibit increased CTSL
and decreased 53BP1 protein levels (Fig. 1 E). This signature
was also observed in MDA-MB-231 breast cancer cells that
overcome the growth arrest induced by depletion of BRCA1
(Fig. S1 B). Similar changes in CTSL and 53BP1 protein levels
were observed with different shRNAs for depletion of BRCA1
(Fig. S1 C). Monitoring transcripts levels by quantitative RT-PCR
(qRT-PCR) revealed transcriptional up-regulation of CTSL in
BOGA cells without significant changes in 53BP1 transcript
levels, indicating a decrease in 53BP1 protein stability (Fig. 1 F).
To confirm a role for BRCA1 in the regulation of 53BP1 levels, we
reconstituted BRCA1 via transient transfection in BOGA cells
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Figure 3. Regulation of 53BP1 IRIF in BOGA cells by vitamin D. (A) Immuno
fluorescence to detect 53BP1 IRIF in control (sh scr) and growth-arrested
BRCA1-depleted cells (shBRCA1) 1 h after 8 Gy of IR. (B) The same assay
was performed as in A but after bypass of growth arrest (BOGA cells).
(C) Immunofluorescence performed in control and BOGA cells treated with
vitamin D or vehicle 24 h before IR. Note how treatment with vitamin D
restores 53BP1 IRIF in BOGA cells. (D) Graph shows the percentage of
cells that form 53BP1 IRIF in the presence of vitamin D or vehicle. Cells
with >10 53BP1 IRIF were considered positive. At least 1,000 cells were
analyzed per condition in one experiment. Error bars were calculated
using the exact binomial test. Asterisk shows p-value of statistical significance (*, P ≤ 0.05). Bars, 10 µm.

and the BRCA1-deficient breast cancer cell line HCC1937.
Ectopic expression of BRCA1 resulted in stabilization of
53BP1 in both cell lines (Fig. 1 G), revealing a novel function
of BRCA1 in the stabilization of 53BP1 protein.
To determine if 53BP1 loss is responsible for the bypass
of growth arrest in BRCA1-deficient cells, we depleted 53BP1
before BRCA1 depletion. As shown in Fig. 2 A, we achieved a
marked reduction of both 53BP1 and BRCA1 proteins. Importantly, previous depletion of 53BP1 prevented the characteristic
growth arrest that follows BRCA1 depletion (Fig. 2 B). These
data indicate that loss of 53BP1 allows BRCA1-deficient cells
to bypass growth arrest. Interestingly, cells that were depleted
of 53BP1 before depletion of BRCA1 also up-regulated CTSL
(Fig. S2 A), suggesting that up-regulation of CTSL is independent of 53BP1 status.
Next, we determined whether CTSL is responsible for
the degradation of 53BP1 in BRCA1-deficient cells by depleting
CTSL in control and BOGA cells (Fig. 2 C and Fig. S2 B).
Depletion of CTSL stabilized 53BP1 protein levels in BOGA
cells, mirroring those of control cells, whereas transcript levels
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CTSL-mediated degradation of
53BP1 rescues HR defects in
BRCA1-deficient cells

BRCA1 deficiency impairs DNA end-resection at DSBs and
formation of RAD51-coated filaments that facilitate subsequent HR steps (Scully et al., 1997a,b; Moynahan et al., 1999;
Snouwaert et al., 1999; Bhattacharyya et al., 2000; Sung et al.,
2003; Schlegel et al., 2006). Interestingly, loss of 53BP1 in
BRCA1-deficient cells partially rescues HR and accumulation
of RAD51 at IR-induced foci (IRIF; Bunting et al., 2010). Here,
we determined how CTSL-mediated degradation of 53BP1 impacts 53BP1 and RAD51 recruitment to DNA DSBs. We show
that growth-arrested MCF7 cells immediately after BRCA1
depletion retained their ability to recruit 53BP1 protein to
IRIF (Fig. 3 A), which is consistent with normal 53BP1 levels.
In contrast, BOGA cells were unable to form 53BP1 IRIF
(Fig. 3 B), which is consistent with their decreased 53BP1 levels.
Next, we determined if the deficiency in 53BP1 foci formation
could be rescued by inhibiting CTSL. BOGA cells treated with
vehicle were defective in the formation of 53BP1 IRIF, whereas
treatment with vitamin D rescued 53BP1 IRIF (Fig. 3, C and D;
and Fig. S3 A).
In contrast to 53BP1, RAD51 recruitment to IRIF was
inhibited shortly after BRCA1 depletion in growth-arrested
cells (Fig. S3 B). This defect was rescued in BOGA cells at
1 h after IR (Fig. 4, A and B). The rescue was not because of
an increase in BRCA1 levels, as BOGA cells were unable to
form BRCA1-labeled IRIF (Fig. S3 C). We tested whether activation of CTSL-mediated degradation of 53BP1 is behind the
rescued recruitment of RAD51 to DSBs in BOGA cells. First,
we show that stabilization of 53BP1 by vitamin D treatment
reduced the extent of RAD51 IRIF (Fig. 4, A and B), revealing

Downloaded from jcb.rupress.org on February 12, 2013

of BRCA1 were not affected by depletion of CTSL (Fig. S2 B).
Intriguingly, we observed a slight increase in BRCA1 protein in
BOGA cells depleted of CTSL, suggesting a possible feedback
mechanism of CTSL on BRCA1 protein levels, a notion that
remains to be tested.
We previously demonstrated that vitamin D inhibits CTSL
activity and stabilizes 53BP1 protein in mouse embryonic fibroblasts (MEFs; Gonzalez-Suarez et al., 2011). Here, we show that
treatment of BOGA cells with vitamin D (1,25-dihydroxy
vitamin D3) stabilized the levels of 53BP1 (Fig. 2 D). Similarly,
treatment with the cathepsin inhibitor E-64 led to increased
levels of 53BP1 protein (Fig. 2 E). These data demonstrate that
cells growth arrested after BRCA1 loss activate CTSL-mediated
degradation of 53BP1 to bypass the growth arrest imposed by
BRCA1 deficiency. In addition, depletion or inhibition of CTSL
can increase 53BP1 levels in the context of BRCA1 deficiency
with potential therapeutic effects. Interestingly, growth arrest
induced by serum deprivation in MCF7 cells also led to decreased levels of BRCA1, up-regulation of CTSL, and downregulation of 53BP1 (Fig. 2 F). These data suggest that BRCA1
might regulate CTSL-mediated degradation of 53BP1 during
the cell cycle and that the growth arrest induced by BRCA1
depletion itself could contribute to the activation of CTSLmediated degradation of 53BP1.

Published January 21, 2013

an unprecedented role for vitamin D in modulating HR. Similarly,
depletion of CTSL reduced the ability of BOGA cells to recruit RAD51 to DSBs (Fig. 4 C). Intriguingly, although control cells formed RAD51 IRIF for up to 6 h, the percentage of
BOGA cells positive for RAD51 IRIF decreased significantly
over time (Fig. 4 D and Fig. S4), indicating that 53BP1 deficiency in BOGA cells does not completely compensate for the
absence of BRCA1. These data demonstrate that by activating
CTSL-mediated degradation of 53BP1, BRCA1-deficient cells
can rescue to a certain extent the HR defects to promote survival and that this pathway can be disrupted by inhibiting CTSL
activity. These findings provide a novel strategy to modulate
HR efficiency in BRCA1-deficient cells.
Consequences of CTSL-mediated
degradation of 53BP1 for DNA repair
and genomic stability

To determine the functional consequences of CTSL-mediated
degradation of 53BP1 in BRCA1-deficient cells, we evaluated
the kinetics of DNA DSB repair by performing comet assays
under neutral, nondenaturing conditions (Olive et al., 1990).
Fig. 5 A shows that BOGA cells exhibited defects in the fast
phase of repair corresponding to classical NHEJ (Iliakis et al.,
2004), which is consistent with our previous finding that upregulation of CTSL in MEFs leads to defects in the fast phase
of repair through degradation of 53BP1 (Gonzalez-Suarez et al.,
2011). Furthermore, inhibition of CTSL with vitamin D rescued the kinetics of DNA DSB repair, mirroring control cells
(Fig. 5 A). These results suggest that CTSL-mediated degradation
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Figure 4. Regulation of RAD51 IRIF in BOGA
cells by CTSL and vitamin D. (A) Immunofluor
escence to detect RAD51 IRIF after 8 Gy of
IR in control and BOGA cells after treatment
with vitamin D or vehicle. Plus denotes positive cells (>10 IRIF) and minus negative cells.
(B) Graph shows the percentage of cells that
form RAD51 IRIF 1 h after IR in the presence
of vitamin D or vehicle. Approximately 1,000
cells were analyzed per condition. Error bars
were calculated using the exact binomial test.
Asterisk shows p-value of statistical significance
(*, P ≤ 0.05). (C) Quantitation of RAD51 IRIF
in control or BOGA cells proficient or deficient
in CTSL showing reduced number of positive
cells in CTSL-depleted BOGA cells. At least
200 cells were analyzed per condition. Error
bars were calculated using the exact binomial
test. Asterisk shows p-value of statistical significance (*, P ≤ 0.05). (D) Quantitation of
percentage of cells positive for RAD51 IRIF
at different times after IR and upon treatment
with vitamin D or vehicle. Note how BOGA
cells exhibit defects in RAD51 IRIF 3 and 6 h
after IR. Bar, 10 µm.

of 53BP1 hinders NHEJ in BRCA1-deficient cells. However,
these cells are still able to repair DSBs although at a lower rate,
suggesting that repair by HR or alternative NHEJ might remain
relatively intact, which is consistent with RAD51 foci being able
to form early after IR.
Cells deficient in HR become dependent on alternative pathways of DNA DSB repair, which often form complex chromosomal aberrations that trigger cell cycle arrest or death. Loss of
53BP1 is sufficient to reduce the extent of aberrant chromosome
structures in BRCA1-deficient cells (Bunting et al., 2010). Here,
we determined whether stabilization of 53BP1 in BRCA1deficient cells exacerbates the extent of genomic instability after
IR by analyzing chromosomal aberrations in metaphase spreads.
We did not find a profound increase in chromosome aberrations
after IR in BOGA cells (Fig. 5 B), in agreement with the deficiency in BRCA1 and 53BP1. However, stabilization of 53BP1
in this context by vitamin D treatment significantly increased the
percentage of metaphases with aberrant chromosomes after IR.
Similarly, stabilization of 53BP1 in BOGA cells by treatment
with the cathepsin inhibitor E-64 markedly increased genomic
instability after IR (Fig. 5 C). Consistent with the increase in
genomic instability, treatment of BOGA cells with vitamin D
or E-64 significantly reduced their recovery from IR (Fig. 5,
D and E). Thus, CTSL inhibition could represent a novel strategy
to induce radiosensitivity in specific types of breast tumors.
To confirm that inhibition of CTSL-mediated degradation
of 53BP1 is responsible for the increase in chromosomal aberrations after IR, we analyzed genomic instability in BOGA cells
depleted of CTSL. These cells showed a marked increase in
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chromosomal aberrations after IR, when compared with cells
deficient in either BRCA1 or CTSL alone (Fig. 6 A). Furthermore, we determined if the effect of vitamin D increasing
genomic instability after IR in BOGA cells is mediated by
53BP1 by monitoring chromosomal aberrations in cells doubly
depleted of 53BP1 and BRCA1. In these cells, the combination
of vitamin D and IR did not result in the profound increase in
genomic instability (Fig. 6 B) that we observed in BOGA cells
(Fig. 5 B). These results demonstrate that vitamin D exerts its
effect in part by stabilizing 53BP1 levels and that the extent of
CTSL-mediated degradation of 53BP1 is a key determinant of the
ability of BRCA1-deficient cells to deal with the DNA damage
generated by IR and putatively other genotoxic agents.
BRCA1-deficient cells are exquisitely sensitive to PARPi
(Bryant et al., 2005; Drew et al., 2011). Importantly, loss of
53BP1 reduces the sensitivity of these cells to PARPi (Bunting
et al., 2010; Aly and Ganesan, 2011). We assessed whether
stabilization of 53BP1 in BOGA cells would increase the extent
of genomic instability induced by PARPi. As shown in Fig. 6 C,
treatment of BOGA cells with PARPi did not result in profound
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genomic instability, in agreement with the resistance of cells
double deficient in 53BP1 and BRCA1 to this treatment. Interestingly, stabilization of 53BP1 by vitamin D increased the extent
of chromosomal aberrations in response to PARPi, suggesting
that inhibition of CTSL-mediated degradation of 53BP1 could
induce sensitivity to PARPi.
Increased levels of nuclear CTSL in TNBC
and tumors from patients with BRCA1
germline mutations

Although CTSL is one of the most abundant proteases in the
endosomal/lysosomal compartment, it has also been identified
in the nucleus (Goulet et al., 2004; Duncan et al., 2008). We
previously showed that up-regulation of CTSL leads to accumulation of the protease in the nucleus and degradation of 53BP1
(Gonzalez-Suarez et al., 2011). Recent studies demonstrated
that loss of 53BP1 is more frequent in TNBC and BRCA1mutated human breast cancer (Bouwman et al., 2010). Here, we
determined whether up-regulation of CTSL occurs in human
breast cancers and if it correlates with decreased levels of

Downloaded from jcb.rupress.org on February 12, 2013

Figure 5. Effect of CTSL inhibition on DNA repair
and genomic stability in BOGA cells. (A) Neutral comet
assays after 8 Gy of IR show higher olive moments,
and thus defects in the fast phase of DNA repair in
BOGA cells. Inhibition of CTSL activity by treatment
with vitamin D (107 M) 24 h before IR rescues defects in DNA DSB repair. (B) Control and BOGA cells
were incubated with vehicle control (C) or vitamin D
(VD) for 24 h before IR with 2 Gy (IR). Cells collected
24 h after IR were analyzed for genomic instability
by quantitating the percentage of metaphases presenting with chromosomal aberrations, as shown in the
images. N, number of independent experiments (50
metaphases analyzed per condition in each experiment). (C) Control and BOGA cells were incubated
with the cathepsin inhibitor (E-64) or vehicle control
(C) for 24 h before IR, and the extent of genomic instability was assessed as in B. (D) Graph shows relative
numbers of BOGA cells 4 d after treatment with IR,
vitamin D, or a combination of both. Treatment protocol
as in B. (E) Graph shows relative numbers of BOGA
cells 4 d after treatment with IR, E-64, or a combination of both. Treatment performed as in C. All values
expressed as mean ± SD. N, number of independent
experiments. Asterisk denotes a p-value of statistical
significance (*, P ≤ 0.05). Bars, 10 µm.
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53BP1. In addition, given the inhibitory effect of vitamin D on
this pathway, we monitored the levels of VDR, which mediates
most of vitamin D’s cellular effects. We performed immunohistochemical analyses of multitumor tissue microarrays (TMAs)
constructed with tissue from 249 patients with sporadic breast
cancer (Fig. 7 and Table 1) classified into four molecular subtypes: luminal A, luminal B, Her2, and triple negative.
Immunohistochemical scores (Hscores; ranging from
0 to 300) for Ki67, ER, CTSL, 53BP1, and VDR provided
a semi-quantitative measurement of their expression for each
tumor subtype (Pallares et al., 2009). As shown in Fig. 7, staining of CTSL was both cytoplasmic and nuclear, whereas 53BP1
staining was only nuclear. Table 1 summarizes the immunohistochemistry results. Whereas cytoplasmic CTSL Hscores were
similar in all tumor subtypes, nuclear CTSL Hscores were markedly enhanced in triple-negative tumors. In agreement with the
in vitro findings, these high nuclear CTSL Hscores concur with
lower 53BP1 Hscores in TNBC compared with all other tumor
types. Furthermore, using the median nuclear Hscores for CTSL
and 53BP1 of 0 and 150, respectively, as cut-off points with
identical statistical power, we confirmed statistically significant
differences in CTSL and 53BP1 expression among molecular
tumor types, with TNBC emerging as a remarkably different
tumor subtype. Table 2 shows that 60% of triple-negative tumors
elicited Hscores for nuclear CTSL >0, a frequency more than
twofold higher than for any other molecular type (P = 0.0013).
Also, 75% of triple-negative tumors expressed 53BP1 Hscores
below 150 compared with 39–49% of all other tumor types
(P = 0.0049), clearly showing that high expression of nuclear
CTSL and low expression of 53BP1 is significantly more asso
ciated with TNBC than any other molecular type. Thus, we
identified nuclear CTSL as a novel biomarker for subsets of TNBC
patients (Fig. S5). Importantly, this new signature (high nuclear
CTSL and low 53BP1) could serve to stratify TNBC patients.
Next, we analyzed breast tumors from patients with
germline mutations in BRCA1 (n = 18) or BRCA2 (n = 14) by
immunohistochemistry (Tables 3 and 4). In comparison with
sporadic TNBC, tumors from patients with BRCA1 germline
mutations elicited the same high Hscores for nuclear CTSL
(P = 0.95) and low Hscores for 53BP1 (P = 1). In contrast,
tumors from patients with BRCA2 germline mutations had
nuclear CTSL Hscores significantly lower than BRCA1related tumors. Accordingly, 53BP1 Hscores were higher in
tumors from patients with BRCA2 germline mutations than
in BRCA1-related tumors or all molecular subtypes of sporadic tumors. These results support our in vitro data for a role
of CTSL in the degradation of 53BP1 in BRCA1-deficient
cells. Importantly, Fig. 8 A shows a statistically significant
inverse linear correlation between Hscores for nuclear 53BP1
and CTSL in all tumor subtypes with positive nuclear CTSL
expression. However, a coefficient of determination of only
6.6% indicates that 93.4% of the variability in 53BP1 Hscores
cannot be accounted for by increases in nuclear CTSL. Thus,
additional factors might contribute to CTSL-mediated degradation of 53BP1 in these tumors. Identifying these factors
could help to discriminate subsets of patients in which this
pathway is activated.

Figure 6. Chromosomal aberrations in response to IR and PARPi.
(A) BOGA cells transduced with an shRNA control (sh scr) or an shRNA for
CTSL were irradiated with 2 Gy and the percentage of cells with aberrant
metaphases was quantified 24 h after IR. A total of 400 metaphases were
analyzed in one experiment (50 per condition). (B) MCF7 cells depleted of
53BP1 and BRCA1 (sh53BP1 + shBRCA1) were treated with vitamin D or
vehicle 24 h before IR, and the percentage of metaphases with aberrant
chromosomes was quantitated. A total of 800 metaphases were analyzed
in one experiment (100 per condition). (C) BOGA cells were treated with
vitamin D (107 M) 24 h before treatment with the PARPi EB-47 (Pi, 1.2 µg/ml)
for an additional 48 h. Graph shows the percentage of metaphases with
chromosomal aberrations. Images show the types of chromosomal aberrations observed. A total of 400 metaphases were analyzed in one experiment (100 per condition). Bar, 10 µm.

Previous studies in human colon cancer cells showed a
correlation between expression of VDR and cystatin D, an inhibitor of several cathepsins including CTSL, and up-regulation of
cystatin D by vitamin D (Alvarez-Díaz et al., 2009). In addition,
our in vitro data show that vitamin D inhibits CTSL-mediated
degradation of 53BP1. Vitamin D actions require a functional
nuclear VDR (Dusso et al., 2005). Because VDR levels are
reduced in several human cancers and BRCA1 loss causes defective VDR translocation to the nucleus (Deng et al., 2009), we
hypothesized that there might be a threshold for nuclear VDR
that inhibits CTSL-mediated degradation of 53BP1. High levels
of nuclear VDR could explain the signature of tumors with high
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Figure 7. A new signature for subsets of TNBC patients. Immunohistochemical analysis was performed in breast tumor TMAs from
249 patients, which included four molecular subtypes: luminal A,
luminal B, Her2, and triple negative. Representative images of
immunohistochemical labeling with Ki67, ER, Her2, CTSL, and
53BP1 are shown. Note that although cytoplasmic CTSL is observed
in all tumor subtypes, nuclear CTSL is markedly up-regulated in
a subset of TNBC. In addition, TNBC tumors exhibit a marked
decrease in 53BP1. Bars, 100 µm.
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patients with TNBC (in which BRCA1 is frequently somatically altered) and tumors from patients with BRCA1 germline
mutations (Tables 2 and 4). Based on our in vitro data, these
signatures could potentially be used as predictors of the response of specific tumors to radiation, cross-linking reagents,
and PARPi.

Discussion
Breast cancers classified as triple negative or BRCA1 deficient are among the most aggressive and difficult to treat. These
tumors harbor similar DNA repair deficiencies and gene expression profiles (Foulkes et al., 2010). Of particular relevance is the
loss of BRCA1 function and decrease in 53BP1 levels, two factors with a decisive role in the choice of DNA DSB repair
mechanisms: HR or NHEJ (Bouwman et al., 2010). Recent
landmark studies demonstrated that loss of 53BP1 allows survival of BRCA1-deficient cells and induces their resistance
to DNA-damaging therapeutic strategies (Cao et al., 2009;
Bothmer et al., 2010; Bouwman et al., 2010; Bunting et al.,
2010). Thus, stabilization of 53BP1 levels represents a promising new strategy for the treatment of these cancers. However,
before this study, no information was available about how the
levels of 53BP1 mRNA and/or protein are down-regulated in
breast tumor cells.
This study demonstrates that up-regulation of CTSL is a
mechanism responsible for lowering 53BP1 protein levels in
BRCA1-deficient cells, allowing bypass of the characteristic
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Hscores for both nuclear CTSL and 53BP1. Our hypothesis is
supported by the findings of a direct linear correlation between
nuclear levels of VDR and 53BP1 for all 249 tumor types (Pearson
correlation r = 0.238; P = 0.0002). By analyzing the linear relationship for those tumors with nuclear VDR expression below
the median Hscore of 120 obtained in the 249 sporadic tumors
(Fig. 8 B), we found an increase in the slope of the linear regression of nuclear 53BP1 and CTSL Hscores as well as increased
coefficient of determination (from 6.6 to 29.2%). Furthermore,
when the correlation between 53BP1 and CTSL was examined
exclusively in TNBC, the nonsignificant correlation depicted in
Fig. 8 C becomes significant when only tumors with nuclear
VDR <120 are examined (P < 0.0027), as seen in Fig. 8 D, with
a coefficient of determination of 80.2%. Indeed, the outliers in
Fig. 8 C correspond to patients with VDR Hscores far above
120, which maintain high Hscores for nuclear 53BP1 despite
high Hscores for nuclear CTSL (Fig. 8 E, top). The bottom
panels of Fig. 8 E show the most common biomarker signature
found in TNBC and BRCA1-related tumors. Furthermore, mean
nuclear Hscores for VDR are lower in tumors from patients with
BRCA1 mutations compared with TNBC (Tables 1 and 3), suggesting that loss of BRCA1 may also impair VDR translocation
to the nucleus. The VDR Hscores in BRCA2 germline mutations depicted in Table 3 suggest that only BRCA1 mutations
impact VDR translocation to the nucleus, resulting in less inhibition of CTSL-mediated degradation of 53BP1.
In summary, this study reveals a new triple biomarker signature—nuclear VDR, CTSL, and 53BP1—for stratification of
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Table 1. Immunohistochemical analysis of CTSL, 53BP1, and VDR expression in sporadic human breast cancer
Proteins

Cytoplasmic CTSL

Nuclear CTSL

53BP1

Cytoplasmic VDR

Luminal A
Luminal B
Erbb2 (1)
Triple negative (1)
Luminal A
Luminal B
Erbb2 (1)
Triple negative (1)
Luminal A
Luminal B
Erbb2 (4)
Triple negative
Luminal A (4)
Luminal B (4)
Erbb2 (2)
Triple negative (3)
Luminal A (4)
Luminal B (4)
Erbb2 (2)
Triple negative (3)

H score

Kruskal-Wallis test
p-value

Mean (SD)

Median [P25, P75]

Min–Max

137 (36.6)
134 (35.2)
141 (43.1)
145 (35.2)
8 (18.0)
8 (14.9)
9 (18.3)
42 (44.3)
155 (56.5)
150 (45.8)
154 (58.1)
112 (44.4)
50 (50.9)
52 (50.8)
53 (48.8)
69 (50.6)
121 (68.2)
125 (65.2)
122 (73.3)
114 (62.3)

135 [110,160]
130 [110,155]
135 [110,171]
140 [120,175]
0 [0, 0]
0 [0, 15]
0 [0, 5]
30 [0, 83]
160 [120, 200]
150 [120, 170]
150 [110, 200]
105 [80, 143]
50 [0, 90]
50 [0, 80]
50 [0, 95]
50 [20, 110]
110 [100, 170]
130 [90, 160]
125 [95, 160]
110 [80, 150]

50–205
75–-230
50–230
80–200
0–90
0–75
0–75
0–125
0–270
40–280
20–300
0–190
0–185
0–190
0–160
0–170
0–300
0–300
0–300
0–270

0.50

<0.0001

0.0002

0.22
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Nuclear VDR

Molecular type

0.78

Values are mean and median Hscores for nuclear and cytoplasmic CTSL, 53BP1, and VDR per tumor type. Min–Max denotes minimal and maximal values within the
tumor subtype. Dispersion is assessed by SD and percentiles 25 and 75 ([P25, P75]); (X) represents X missing values per molecular type as a result of insufficient
specimen. Bolded Hscore values highlight the molecular subtype responsible for the statistically significant difference identified with the Kruskal-Wallis test that compares all molecular types (bold p-value if significant difference).

growth arrest upon loss of BRCA1 function (Fig. 9). It is possible
that other mechanisms such as degradation of 53BP1 by the proteasome also contribute to 53BP1 reduction in BRCA1-deficient
tumor cells. In addition, previous studies showed that subsets
of BRCA1-mutated tumors also exhibit reduced 53BP1 mRNA
levels (Bouwman et al., 2010), indicating that different mechanisms can be activated in BRCA1-deficient cells to lower 53BP1
levels and ensure survival. Importantly, depletion of CTSL or
inhibition of its activity stabilizes 53BP1 protein levels and induces genomic instability in BRCA1-deficient cells after IR or
treatment with PARPi.
Furthermore, we show a significant negative correlation
between 53BP1 and nuclear CTSL in human tumors. The highest median levels of nuclear CTSL concur with the lowest levels
of 53BP1 in a subset of TNBC and tumors from patients with
BRCA1 germline mutations and with low nuclear VDR levels.
This study has revealed a new pathway, activated upon loss of
BRCA1 function, which is anticipated to contribute to the progression of breast cancers with the poorest prognoses. Inhibition
of this pathway by treatment with vitamin D or cathepsin inhibi
tors could provide a new therapeutic strategy for breast cancer.
Importantly, the status of the pathway offers great potential
as a predictive biomarker for response to therapy.
CTSL up-regulation after growth arrest by
BRCA1 loss and serum deprivation

In a variety of cancers, up-regulation of CTSL has been associated with increased invasiveness, metastasis, and overall degree of malignancy (Jedeszko and Sloane, 2004; Skrzydlewska

et al., 2005; Gocheva and Joyce, 2007). Thus, inhibition of CTSL
activity could represent a strategy for cancer treatment (Lankelma
et al., 2010). Our previous studies in MEFs revealed novel roles
for CTSL in the degradation of nuclear factors with functions
in cell cycle regulation (Rb family members) and DNA repair
(53BP1; Gonzalez-Suarez et al., 2011). The present study shows
that CTSL is up-regulated in breast cancer cells after BRCA1
depletion and that increased CTSL activity impacts mechanisms
Table 2. Frequency of CTSL, 53BP1, and VDR expression within
molecular subtype relative to the median values in sporadic human
breast cancer
Proteins
Nuclear CTSL >0

53BP1 <150

Nuclear VDR <120

Molecular type

n (%)

Fisher exact test
p-value

Luminal A
Luminal B
Erbb2 (1)
Triple negative (1)
Luminal A
Luminal B
Erbb2 (4)
Triple negative
Luminal A
Luminal B
Erbb2 (4)
Triple negative

23 (23.2)
22 (31.9)
12 (27.3)
21 (60.0)
59 (59.6)
35 (50.7)
21 (51.2)
9 (25.0)
46 (48.4)
40 (61.5)
25 (58.1)
16(48.5)

0.0013

0.0049

0.34

Values denote the absolute (n) and the relative (%) frequencies of tumors with
Hscore values above (nuclear CTSL) or below (nuclear 53BP1 and VDR) the median Hscore values for each protein in the overall population of sporadic breast
cancer. Bolded frequency values highlight the molecular subtype responsible
for the statistically significant difference identified with the Fisher exact test that
compares all molecular types (bold p-value if significant difference).
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Table 3. Immunohistochemical analysis of CTSL, 53BP1, and VDR expression in tumors from patients with BRCA1 or BRCA2 germline mutations
Proteins

Cytoplasmic CTSL

Nuclear CTSL

53BP1

Cytoplasmic VDR

Mutation type

60–190

0.0563

100–150

0.0437

0–180

0.0001

0–75

0.19

(1)

118 (46.2)

BRCA1 mutation

(4)

38 (45.2)

BRCA2 mutation

(1)

15 (22.7)

BRCA1 mutation

(1)

111 (28.4)

BRCA2 mutation

(1)

198 (43.6)
86 (38.5)
145 (36.7)

BRCA2 mutation

66 (52.9)
175 (57.8)

(3)

70–175

0.0016

110–270

0.0008

0–150

0.0048

100–200

<0.0001

0–180

0.0010

110–300

0.0074

0.0494

0.0001

0.0011

0.0001

Values are mean and median Hscores for nuclear and cytoplasmic CTSL, 53BP1, and VDR in BRCA1- or BRCA2-related tumors. Min–Max denotes minimal and
maximal values within the tumor. Dispersion is assessed by SD and percentiles ([P25, P75]); (X) represents X missing values. Bolded p-values highlight the statistical
significance of differences measured by Mann-Whitney test (M-W) between each tumor mutation subtype versus the overall population of sporadic breast cancer or
between tumors with BRCA1 versus BRCA2 germline mutations.

of DNA DSB repair. Several lines of evidence implicate BRCA1
in transcriptional regulation, chromatin remodeling (Bochar
et al., 2000; Mullan et al., 2006), and maintenance of heterochromatin silencing (Zhu et al., 2011). Epigenetic mechanisms such as
DNA methylation and expression of miRNAs have been linked
to BRCA1 function (Shukla et al., 2010; Kawai and Amano, 2012;
Tanic et al., 2012). Although the mechanism by which BRCA1deficient cells activate CTSL remains unknown, the latency in
the activation of this pathway indicates that CTSL is not a direct
transcriptional target of BRCA1. Rather, we speculate that the
loss of BRCA1 might result in alterations in chromatin structure
that either make the CTSL gene more permissive to transcriptional activation over time and/or alter the stability of CTSL

mRNAs. Those BRCA1-deficient cells that are able to activate
CTSL-mediated degradation of 53BP1 would be poised to continue proliferation.
Furthermore, we show that cells growth arrested in G0/G1
by serum deprivation also exhibit low BRCA1, high CTSL, and
low 53BP1 levels, suggesting a functional relationship between
these proteins during the cell cycle. We envision a model where
the decrease in BRCA1 levels in G0/G1 phases contributes to
CTSL-mediated degradation of 53BP1. Up-regulation of CTSL
could also trigger a feedback mechanism that lowers BRCA1
protein levels. This is supported by studies showing that BRCA1
is a target for degradation by cysteine proteases of the cathepsin family, although the specific cathepsin was not identified

Table 4. Frequency of CTSL, 53BP1, and VDR expression within BRCA1- and BRCA2-related tumors
Proteins

Nuclear CTSL >0
53BP1 <150
Nuclear VDR <120

Mutation type

BRCA1
BRCA2
BRCA1
BRCA2
BRCA1
BRCA2

mutation
mutation
mutation
mutation
mutation
mutation

n (%)

(4)
(1)
(1)
(1)
(1)
(1)

12
7
2
11
3
8

(85.7)
(53.8)
(11.8)
(84.6)
(16.7)
(72.7)

Fisher exact test
p-value
(vs. sporadics)

Fisher exact test
p-value
(BRCA1 vs. BRCA2)

0.0001
0.13
0.0019
0.0210
0.0027
0.35

0.10
0.0001
0.0051

Values denote the absolute (n) and the relative (%) frequencies of BRCA1- or BRCA2-related tumors with Hscore values above (nuclear CTSL) or below (nuclear
53BP1 and VDR) the median Hscore values for each protein in sporadic breast tumors. Bolded p-values highlight the statistically significant difference measured
by Fisher exact test comparing a molecular subtype with either the overall population of sporadic breast cancer or between tumors with BRCA1 versus BRCA2
germline mutations.
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110
[100, 138]
120
[100, 120]
30
[15, 45]
4
[0, 15]
115
[100, 125]
210
[185, 220]
100
[50, 100]
150
[115, 165]
53
[27, 100]
170
[135, 193]

BRCA2 mutation

BRCA1 mutation

0.88

Min–Max

119 (34.2)

(3)

M-W test
p-value
(BRCA1 vs. BRCA2)

Median
[P25, P75]

(4)

BRCA1 mutation

M-W test
p-value
(vs. sporadics)

Mean (SD)
BRCA1 mutation

BRCA2 mutation
Nuclear VDR

H score
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(Blagosklonny et al., 1999). Future studies need to determine
if CTSL functions as a regulator of 53BP1 and BRCA1 protein
stability during the cell cycle.
Vitamin D and cathepsin inhibitors can
modulate DNA DSB repair choice

Our previous study in MEFs (Gonzalez-Suarez et al., 2011)
and the present study in human breast cancer cells reveal an
unprecedented role for vitamin D and cathepsin inhibitors in
the regulation of DNA DSB repair choice. By stabilizing 53BP1
protein levels in the context of BRCA1 deficiency, CTSL inhibitors facilitate repair of DSBs by NHEJ while inhibiting
HR. Importantly, our data indicate that both vitamin D and
cathepsin inhibitors impact 53BP1 stability, especially in cells
that up-regulate CTSL, i.e., BRCA1-deficient cells, showing
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Figure 8. Nuclear 53BP1 expression correlates inversely with nuclear CTSL expression
in sporadic human breast cancer. (A–D) Linear
regression analysis between Hscores for nu
clear 53BP1 and CTSL in sporadic breast cancer
samples with Hscores for nuclear CTSL >0.
Note the high variability in nuclear 53BP1
Hscores in tumors without nuclear CTSL. The
linear regression analysis of the association
between nuclear 53BP1 and CTSL depicted
in A (linear regression coefficient r= 0.42;
P = 0.02; coefficient of determination r2 =
6.6%) and B (r = 0.93; P = 0.0025; r2 =
29.2%) include Hscores from both TNBC and
no TNBC tumors, whereas C (r = 0.255;
P = 0.294; r2 = 5.8) and D (r = 0.89;
P = 0.0027; r2 = 80.2%) depict TNBC only.
Note the marked increase in percentage of
the variability in nuclear 53BP1 levels that
can be explained by changes in nuclear CTSL
parameters of B and D when only tumors with
nuclear VDR Hscores <120 are included in
the regression analysis. (E) Images of immuno
histochemical analysis results in TNBC patients. Two different signatures were observed
in these patients (as well as in patients with
BRCA1 germline mutations). Top panels show
the signature of a few TNBC patients: high
nuclear CTSL, 53BP1, and VDR. Bottom panels show the most common signature in TNBC
patients: high nuclear CTSL, low 53BP1, and
low nuclear VDR. Bars, 100 µm.

a lesser effect in cells with normal CTSL expression. This is
likely because up-regulation of CTSL leads to an increase in the
levels of nuclear CTSL, which is low relative to other cellular
compartments in normal cells (Gonzalez-Suarez et al., 2011).
Although our attempts to localize nuclear CTSL in MCF7
BOGA cells by Western blot were unsuccessful, the immunohistochemical analysis of TMA clearly showed that a subset of
TNBC and BRCA1-deficient tumors present with high levels of
nuclear CTSL. Interestingly, these tumors are often also deficient in nuclear VDR and 53BP1.
The ability to impact the choice of DNA DSB repair pathway could have profound consequences for cancer therapy. In
tumor cells that activate CTSL-mediated degradation of 53BP1
as a means to ensure survival, cathepsin inhibition could stabilize 53BP1, increase genomic instability, and induce growth
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arrest and/or cell death, especially in combination with IR or
PARPi. Thus, treatment with vitamin D or CTSL inhibitors could
represent a new therapeutic strategy for specific types of breast
tumors, if they can be identified.
Nuclear levels of CTSL, 53BP1, and VDR:
a new predictive biomarker signature for
drug response?

The analysis of TMA indicates that levels of nuclear CTSL represent a new positive biomarker for subsets of tumors having
abnormalities in BRCA1, including TNBC (currently defined
solely by the absence of Her2/neu, estrogen and progesterone
receptors, and frequently showing somatic alterations of BRCA1
function), and tumors arising in association with germline
mutations in BRCA1. Similarly, we find that nuclear VDR levels
correlate linearly with 53BP1 content in all tumor subtypes, and
the lowest nuclear VDR levels correspond to TNBC and tumors
from patients with BRCA1 germline mutations. The finding of
the strong negative correlation between reductions in nuclear
53BP1 with increases in nuclear CTSL levels (80% coefficient
of determination) in TNBC with nuclear VDR <120 is very
interesting, as TNBC is associated with severe vitamin D deficiency (Peppone et al., 2011). Furthermore, a previous study


198

JCB • VOLUME 200 • NUMBER 2 • 2013

Materials and methods
Cells maintained in DMEM, 10% FBS, and antibiotics/antimycotics were
transduced with shRNAs and selected in media containing 0.5 mg/ml Geneticin G418 or 2 µg/ml puromycin. Except for one shBRCA1 (5-TCAGTACAATTAGGTGGGCTT-3) that was constructed by J. Zhang, the rest were
purchased from the Genome Institute at Washington University (shBRCA
sequences: 1, 5-GAGAATCCTAGAGATACTGAA-3; 2, 5-TATAGCTGTT
GGAAGGACTAG-3; 3, 5-CCCTAAGTTTACTTCTCTAAA-3; 4, 5-GCC
CACCTAATTGTACTGAAT-3; 5, 5-CCCACCTAATTGTACTGAATT-3).
Lentiviral transductions were performed as previously described
(Gonzalez-Suarez et al., 2009). In brief, 293T cells were transfected with
viral packaging (pHR’8.2R) and envelope (pCMV-VSV-G) plasmids along
with the vector containing the shRNA of interest. After 48 h, viral media
was collected and used to infect target cells in one 4–6-h infection.
Cells were allowed to recover for 48 h and treated with the appropriate
selection drug. Viral packaging and envelope plasmids were gifts from
S. Stewart (Washington University, St. Louis, MO). HCC1937 cells were
a gift from J. Zhang (Washington University, St. Louis, MO). HA-BRCA1
(Addgene) transient transfections were performed using the X-tremeGENE
HP transfection reagent (Roche). For growth arrest by serum deprivation,
MCF7 cells were incubated in DMEM, 0.1% FBS, and antibiotics/antimycotics for 48 h. DNA content was monitored after ethanol fixation and
propidium iodide labeling (1 mg/ml in water).
Cell treatments
Vitamin D. Cells were incubated with 107 M 1,25-dihydroxyvitamin D3

(Sigma-Aldrich) for 24–48 h, as indicated. Aliquots of 1 nmol 1,25dihydroxyvitamin D3 were resuspended in 1 ml BGS and diluted in DMEM
to a final concentration of 10% BGS. BGS was the vehicle control.
E-64. Cells were incubated with the broad-spectrum cathepsin inhibitor
E-64 (Sigma-Aldrich) diluted in water at a concentration of 10 µM for 24 h.
PARPi. Cells were treated with the PARPi EB-47 (Sigma-Aldrich)
diluted in water at a concentration of 1.2 µg/ml for 48 h.
IR. For determining the extent of genomic instability, cells were irradiated with 2 Gy and analysis of metaphase spreads was performed 24 h
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Figure 9. Activation of CTSL-mediated degradation of 53BP1 allows
BRCA1-deficient cells to overcome genomic instability and growth arrest.
Depletion of BRCA1 in breast cancer cells leads to defects in HR, genomic
instability, and growth arrest. Over time, BRCA1-deficient cells activate
CTSL-mediated degradation of 53BP1, which rescues HR defects while
inhibiting NHEJ. This allows BRCA1-deficient cells to overcome growth arrest. Inhibition of CTSL activity via treatment with vitamin D or specific
inhibitors stabilizes 53BP1 protein levels and induces genomic instability
in response to IR and PARPi. Furthermore, up-regulation of CTSL-mediated
degradation of 53BP1 could be regulated by nuclear VDR.

showed a role for VDR in the up-regulation of cathepsin inhibitors
(Alvarez-Díaz et al., 2009). Thus, it is tempting to speculate that
vitamin D interventions could lead to VDR-induced expression
of cystatins and the attenuation of CTSL-mediated degradation
of 53BP1. Future studies testing this hypothesis might lead to
new strategies of targeted therapy.
The combination of low nuclear VDR or high nuclear
CTSL with low 53BP1 levels offers great potential for the stratification of BRCA1-deficient and TNBC patients into different
subgroups and as a predictive biomarker for the response of
these patients to current therapies. In particular, the use of PARPi
as single agents or in combination with radiation or chemotherapy is a leading strategy for breast cancer management, especially for HR-deficient tumors (Farmer et al., 2005; Helleday
et al., 2005; Fong et al., 2009; Tutt et al., 2010; Drew et al.,
2011). However, a significant fraction of these cancers acquire
resistance to PARPi. A recent study in cell culture and mouse
models demonstrated that loss of 53BP1 reduces the sensitivity
of BRCA1-deficient cells to PARPi (Bunting et al., 2010).
Our study suggests that BRCA1-deficient and TNBC
patients that exhibit low nuclear VDR, high nuclear CTSL, and
low 53BP1 levels are likely to be proficient in HR and resistant
to PARPi. Therefore, these patients will not benefit from this
specific treatment unless levels of 53BP1 are stabilized. For
these patients, treatment with vitamin D or CTSL inhibitors to
stabilize 53BP1 levels in combination with PARPi might result
in the most effective therapy.
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after IR. For assaying formation of IRIF, cells were irradiated with 8 Gy and
fixed and processed for immunofluorescence 1, 3, or 6 h after IR as indicated. For comet assays, cells were irradiated with 8 Gy.
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, and 0.5% SDS) supplemented
with PMSF, protease inhibitors (Sigma-Aldrich), and 20 mM DTT. Protein
detection was performed using the following antibodies: BRCA1 (Santa
Cruz Biotechnology, Inc.), 53BP1 (Novus Biologicals), CTSL (Santa Cruz
Biotechnology, Inc.), -Tubulin (Sigma-Aldrich), and p107 (Santa Cruz
Biotechnology, Inc.).

Comet assay
Neutral comet assays were performed using CometSlide assay kits (Trevigen). Treated cells were irradiated with 8 Gy and incubated at 37°C for different periods of time to allow DNA to repair (0, 30, 60, and 90 min). Cells
were embedded in agarose, lysed, and subjected to neutral gel electrophoresis. Cells were stained with ethidium bromide and visualized using a fluor
escence microscope. Olive comet moments were calculated by multiplying
the percentage of DNA in the tail by displacement between the means of the
head and tail distributions as described previously (Olive et al., 1990). The
program CometScore Version 1.5 (TriTek) was used to calculate olive moments. A total of 30 comets were analyzed per sample in each experiment.
Proliferation assay
To quantify growth upon depletion of BRCA1, cells were plated in triplicate at 150,000 cells/well and counted 96 h later. Cell proliferation was
measured in each cell line four times within a 14-d period. To quantify the
growth of the sh53BP1/shBRCA1 cells, 4 × 106 cells were plated in 15-cm
dishes and counted every 96 h for 20 d. To extrapolate proliferation to the
respective time periods, we used the equation N = N0ekt where N is the final
number of cells, N0 is the starting number of cells, k is ln2/DT (doubling
time), and t is time in days (Sherley et al., 1995). For each 96-h period we
calculated the doubling time and used it to estimate the number of cells (N)
that would result from initially plating 150,000 (N0) and cultured them for
a given period of time. The doubling times for the control cells remained
constant throughout the time period, whereas the doubling times for the
shBRCA1 cells started increasing once the cells overcame the growth arrest.
qRT-PCR
RNA was isolated using the RNAqueous-4PCR kit (Ambion). cDNA was
generated from 500 ng of total RNA using TaqMan Reverse Transcription

Analysis of aberrant chromosomes
Cells were treated with vitamin D or E-64 for 24 h, irradiated, and allowed to recover for 24 h. Cells treated with PARPi were pretreated with
vitamin D for 24 h followed by combined treatment with vitamin D and
PARPi for 48 h. After all treatments, cells were arrested in mitosis by treatment with colcemid for 4 h and metaphase spreads were prepared by
hypotonic swelling in 0.56% KCl, followed by fixation in 3:1 methanol/
acetic acid. Cell suspensions were dropped onto slides and stained for
25 min in Wright-Giemsa Stain (Ricca Chemical Company) and then
washed in water. Slides were allowed to dry and were mounted using
Eukitt Mounting Reagent (Sigma-Aldrich) and analyzed at room temperature on a DM5000 B microscope using a 100× oil objective (NA 1.30).
Images were acquired with the DFC350 FX digital camera using the
Application Suite.
TMAs
A total of 249 tissue samples from patients with sporadic breast carcinoma were obtained at Hospital Universitari Arnau de Vilanova in
Lleida, Lleida, Spain, from 1998 to 2012. An informed consent was ob
tained from each patient and the study was approved by the local Ethical Committee. The series of 249 tumor samples included formalin-fixed,
paraffin-embedded blocks for all patients, 165 core biopsies, before the
initiation of neoadjuvant treatment, and 84 surgical specimens, before
the initiation of adjuvant treatment. Tumors were classified according
to the expression of proteins Ki67, Er, and Her2 into four molecular
subtypes: luminal A (n = 99), luminal B (n = 69), Her2 (n = 45), and
triple negative (n = 36). Luminal A tumors are steroid hormone receptor
positive, are negative for Her2, contain less than 30% of Ki67 positive
cells, and tend to have a good prognosis. Luminal B tumors are steroid
hormone receptor–positive, negative for Her2, contain more than 30%
Ki67-positive cells, and tend to have a worse prognosis than luminal A.
In contrast, Her2 tumors are positive for Her2 and have been shown to
have a poor prognosis. Triple-negative tumors are negative for steroid
hormone receptors and Her2 and have the worst prognosis. Moreover,
tissue samples were also obtained from 18 breast cancers from patients
carrying a BRCA1 germline mutation (luminal A, n = 1; luminal B, n = 1;
Her2, n = 2; triple negative, n = 15), and from 14 breast cancers from patients carrying a BRCA2 germ-line mutation (luminal A, n = 6; luminal B,
n = 2; Her2, n = 3; triple negative, n = 3). These patients had been
treated in Hospital Santa Creu I Sant Pau, Barcelona, Spain.
We used a tissue arrayer device (Beecher Instrument) to construct the
TMAs. Representative areas of all samples were marked in the corresponding paraffin blocks. In each sample, we selected two cylinders (0.6 mm
of largest diameter) for the immunohistochemical analysis.
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Immunofluorescence
For immunofluorescence of RAD51 and 53BP1, cells were plated on coverslips
and fixed in 3.7% formaldehyde and 0.2% Triton-X 100 in PBS for 10 min
at room temperature. Coverslips were washed and blocked for 1 h at 37°C
in 1% BSA and 0.1% Triton X-100 in PBS. Incubation with antibodies recognizing RAD51 (1:200; Santa Cruz Biotechnology, Inc.) or 53BP1 (1:1,000;
Novus Biologicals) was performed for 1 h at 37°C, followed by washing in
PBS and incubation with Alexa Fluor 488 goat anti–rabbit (1:1,000; Invitrogen) secondary antibody for 1 h at 37°C. After washing in PBS, coverslips
were mounted using Vectashield with DAPI (Vector Laboratories).
BRCA1 immunofluorescence was performed following a protocol
from the Fernandez-Capetillo laboratory (Centro Nacional de Investigaciones Oncológicas, Madrid, Spain). In brief, cells were washed twice
with PBS and incubated in CSK I buffer (10 mM Pipes, pH 6.8, 100 mM
NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, and 0.5% Triton
X-100) for 5 min. Coverslips were washed five times with cold PBS and
fixed in modified STF buffer (150 mM 2-Bromo-2-nitro-1,3-propanediol,
108 mM diazolidinyl urea, 10 mM sodium citrate, and 50 nM EDTA, pH 5.7)
for 30 min at room temperature. Coverslips were then washed twice with
cold PBS and permeabilized (PB buffer: 100 mM Tris-HCl, pH 7.4, 50 mM
EDTA, pH 8.0, and 0.5% Triton X-100) for 15 min at room temperature
followed by two washes in PBS. Blocking, antibody staining, and mounting were performed as previously described with BRCA1 antibody (Santa
Cruz Biotechnology, Inc.) diluted at 1:200 and Alexa Fluor 594 goat anti–
mouse secondary antibody (Invitrogen) diluted at 1:1,000.
Microscopy and photo capture was performed at room temperature
on either an Eclipse 90i microscope (Nikon) using 60 or 100× oil objective lenses (NA 1.4 and 1.45, respectively) with a CoolSNAP ES2 digital
camera (Photometrics) and MetaMorph (Version 7.1.2.0) or a DM5000 B
microscope (Leica) using 63 or 100× oil objective lenses (NA 1.4 and 1.3,
respectively) with a DFC350FX digital camera (Leica) and the Application
Suite (Version 4.1.0; Leica).

Reagents (Applied Biosystems). BRCA1, 53BP1, CTSL, and 18S expression
was determined using TaqMan Gene Expression Assays (Hs01556193_m1,
Hs00996818_m1, Hs00377632_m1, and Hs99999901_s1; Applied
Biosystems). All the reactions were performed in triplicate and the target
gene and endogenous controls were amplified in the same plate. Relative
quantitative measurements of target genes were determined by comparing
the cycle thresholds.

Immunohistochemical analysis
TMA blocks were sectioned at a thickness of 3 µm, dried for 1 h at 65°C
before being dewaxed in xylene and rehydrated through descending concentrations of ethanol, and washed with PBS. Ki67, ER, and Her2 were
used to determine molecular subtype. Comparative studies of CTSL, VDR,
and 53BP1 expression were performed on sequential serial sections. Antigen retrieval for CTSL and ER was achieved by heat treatment at 95°C for
20 min in a high pH solution (Dako). Heat-induced antigen retrieval for
53BP1 and Ki67 was performed in a low pH solution (Dako). Before staining the sections, endogenous peroxidase was blocked. Primary antibodies
and incubation times were as follows: CTSL (1:50; Santa Cruz Biotechnology, Inc.; incubation overnight at 4°C); 53BP1 (1:2,500; Novus Biologicals; incubation 20 min at room temperature); VDR (1:2,000; Abcam;
incubation 20 min at room temperature); Ki67 (Ready-to-use; Dako; incubation 20 min at room temperature); ER (Ready-to-use; Dako; incubation
20 min at room temperature), and Her2 (Herceptest kit; Dako). The reaction was visualized with the Streptovidin-Biotin Complex (Dako) for CTSL
and Envision Flex (Dako) for 53BP1, Ki67, and ER. Sections were counterstained with hematoxylin. Appropriate positive and negative controls
were also tested.
Hscores provide a semiquantitative measurement of protein expression per tumor by taking into consideration the percentage of positive
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cells and the intensity of their staining. An Hscore ranging from 0
(no immune reaction) to 300 (maximal immunoreactivity) was obtained with
the formula Hscore = 1× (% light staining) + 2× (% moderate staining)
+ 3× (% strong staining). The reliability of such scores for the interpretation
of immunohistochemical staining in TMAs has been reported previously
(Pallares et al., 2009).
Her2 staining was evaluated according to a standard protocol (Hercep
Test; Dako) and scored as four intensities (i.e., negative = 0; weak = 1+;
moderate = 2+; and strong = 3+), considering negative Her2 expression
for intensity values of 0, 1+, and 2+ when there was no amplification
by FISH and positive for intensity values of 3+ and 2+, when 2+ was
amplified by FISH. For each marker, there were a variable number of nonassessable cases caused by technical problems including no representative tumor sample left in the cylinders, detachment, cylinders missed while
constructing the array, necrosis, and absence of viable tumor cells in the
TMA sections.

Online supplemental material
Fig. S1 shows an entire BRCA1 Western blot as well as Western blots
of activation of CTSL-mediated degradation of 53BP1 in MDA-MB-231
cells and by different BRCA1 shRNAs. Fig. S2 shows qRT-PCR results for
the sh53BP1/shBRCA1 and the shBRCA1/shCTSL doubly depleted cells.
Fig. S3 shows results from immunofluorescence studies of 53BP1, BRCA1,
and RAD51 IRIF in the generated cell lines and upon different treatments.
Fig. S4 shows RAD51 foci formation data at 3 and 6 h after IR. Fig. S5
shows differences in CTSL levels among different molecular subtypes of
breast cancer. Online supplemental material is available at http://www
.jcb.org/cgi/content/full/jcb.201204053/DC1.
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Statistical analysis
For the in vitro experiments, a two-tailed student’s t test was used to calculate
statistical significance of the observed differences. Excel 2010 (Microsoft)
was used for the calculations. In all cases, differences were considered statistically significant when P < 0.05. For some figures the 95% confidence interval based on an exact binomial distribution was calculated to determine
significant differences among samples. For the TMA studies, a Kruskal-Wallis
test was used to test the statistical significance of the observed differences in
CTSL, VDR, and 53BP1 Hscores between molecular breast tumor subtypes.
Tumors were partitioned according to cut-off nuclear Hscores for CTSL,
53BP1, and VDR selected by their median values as >0, <150, and <120,
respectively. Once cut-off points were applied, Fisher exact test was used to
assess the statistical significance of the differences in the distribution of the
two categories of CTSL, 53BP1, and VDR Hscores above or below cut-off
points for all breast tumor types. In the analysis of BRCA1 and BRCA2 samples, we used the Mann-Whitney test to analyze Hscore differences between
them as well as differences of each of them with the sample of sporadic tumors, and we used the Fisher exact test to assess differences in the distributions of groups defined by the same cut-off points used for the sporadic
tumors. The subsample of TNBC was also compared with the sample of germinal BRCA1 mutated cancers using the same statistical tests. The Pearson
correlation coefficient together with linear regression models assessed the
statistical significance of the relationship between nuclear CTSL and 53BP1
Hscores. R package was used to perform all TMA statistical tests. Differences
were considered significant when P < 0.05.
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